Viracta Therapeutics to Present at the Jefferies Virtual Healthcare Conference

 

SAN DIEGO, May 27, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that Company management will present at the Jefferies Virtual Healthcare Conference taking place June 1-4, 2021. The Company will also participate in one-on-one investor meetings at the conference.

Details on the presentation can be found below.

Date:

Thursday, June 3, 2021

Time:

2:30 PM ET

Format:

Corporate presentation

Webcast:

https://wsw.com/webcast/jeff174/virx/1890351

A replay of the presentation will be available on the "Events and Webcasts" section of the Viracta website at https://viracta.investorroom.com/events-and-webcasts#past.

About Viracta Therapeutics, Inc.
Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.

For additional information please visit www.viracta.com.

Investor Relations Contact:                    

Company Contact:

Joyce Allaire                       

Dan Chevallard

LifeSci Advisors                                                  

Chief Operating Officer and Chief Financial Officer

jallaire@lifesciadvisors.com                      

dchevallard@viracta.com  

(212) 915-2569                                        

(858) 771-4193

 

Viracta Therapeutics, Inc. Logo (PRNewsfoto/Viracta Therapeutics, Inc.)

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/viracta-therapeutics-to-present-at-the-jefferies-virtual-healthcare-conference-301301289.html

SOURCE Viracta Therapeutics, Inc.

 

Back to news